相关实验视频

Updated: Jan 12, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

工程化凝血因子VIII,增强血友病A基因治疗的分泌和凝血潜力

Yuji Kashiwakura¹, Yuto Nakajima², Kio Horinaka³

¹Jichi Medical University, Shimotsuke, Japan.

|November 6, 2025

概括

研究人员为血友病A基因治疗设计了一种新型的第八因子变异 (FVIIISQ). 这种增强的FVIIISQ显示出更好的分泌和凝血,可能使较低的腺相关病毒 (AAV) 载体剂量获得稳定,长期的治疗疗效.

科学领域:

基因治疗基因治疗
血液学血液学血液学
分子生物学分子生物学

背景情况:

血友病A的基因疗法面临的挑战是腺相关病毒 (AAV) 载体剂量和持续的第八因子 (FVIII) 表达.
开发改进的FVIII变种对于提高治疗结果至关重要.

研究的目的:

设计人类B域删除的FVIII (FVIIISQ) 变种,具有增强的分泌和凝固特性.
在血友病A的临床前模型中评估携带工程FVIIISQ的AAV载体在血友病A的疗效.

主要方法:

开发了工程人类B域删除的FVIIISQ变体.
携带工程FVIIISQ的AAV载体被注射给A型血友病小鼠和.
评估了FVIII活性,抗原水平和与激活的凝血因子IX的结合.

主要成果:

改造后的FVIIISQ显示了细胞内积累的减少和蛋白质反应的展开.
与工程 FVIIISQ 的 AAV 载体导致小鼠的 FVIIII 活性和抗原水平明显更高,与野生型 FVIIISQ 相比.
改造后的FVIIISQ具有3.6倍更高的特异性活性,并增强了与激活的凝血因子IX的结合.
在子中,AAV5工程FVIIISQ的单次低剂量实现了超生理FVIII活性.

结论:

工程化FVIIISQ变种显示出在A型血友病中改善腺相关病毒介导基因疗法的潜力.
这些变异可能会在减少载体剂量时实现稳定,长期的治疗疗效.
进一步开发FVIIISQ可以克服血友病A基因治疗当前的局限性.

更多相关视频

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Recombinant DNA

Recombinant DNA